-+ 0.00%
-+ 0.00%
-+ 0.00%

The Zhitong Finance App learned that on Wednesday, biotech company Attovia Therapeutics (ATTO.US) officially landed on the NASDAQ and closed up 28.82% on the first day of listing to $21.9. The IPO price is $17. Established in 2022, Attovia's core technology “ATTOBODY” platform is a biotechnology platform based on biparatopic nanoantibodies (biparatopic nanobody), obtained an exclusive license from Alamar Biosciences (ALMR.US). The platform enables the development of multi-specific antibody therapies targeting complex immune targets.

Zhitongcaijing·08/05/2026 23:18:40
Listen to the news
The Zhitong Finance App learned that on Wednesday, biotech company Attovia Therapeutics (ATTO.US) officially landed on the NASDAQ and closed up 28.82% on the first day of listing to $21.9. The IPO price is $17. Established in 2022, Attovia's core technology “ATTOBODY” platform is a biotechnology platform based on biparatopic nanoantibodies (biparatopic nanobody), obtained an exclusive license from Alamar Biosciences (ALMR.US). The platform enables the development of multi-specific antibody therapies targeting complex immune targets.